Insider · CIK 0002022347
Andrew M. Dahl
Files at EW (Edwards Lifesciences Corp). First filing May 29, 2026, latest May 29, 2026.
Andrew M. Dahl files SEC Form 4 as officer at EW (Edwards Lifesciences Corp). Since May 29, 2026, Andrew M. Dahl has reported 0 open-market buys worth $0 and 1 open-market sell worth $49k, the latest filed on May 29, 2026.
A track record needs three past buys with six months of prices behind them; Andrew M. Dahl has 0, so none is measured yet.
The newest scored trade: sold $49k of EW on May 29, 2026, filed May 29, 2026, scored 37 (weak). In the last 12 months: 0 buys worth $0 and 1 sell worth $49k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
EW: Edwards Lifesciences Corp
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 37Weak | Edwards Lifesciences Corp | $49k 568 shares | -4% | +19% from low-1% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 31, 2026 | EW Edwards Lifesciences Corp | 544 0.00% of outstanding | $50k | Aug 31, 2026 | none |
| May 29, 2026 | EW Edwards Lifesciences Corp | 568 0.00% of outstanding | $49k | May 29, 2026 | none |
Transactions
Every row this insider has filed, 12 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 13, 2026 | EW Edwards Lifesciences Corp | FTax withholding Common Stock | -253 | $84.37 | $21k | 14,615 | 29 d ago |
| May 29, 2026 | EW Edwards Lifesciences Corp | SOpen-market sale Common Stock | -568 | $86.08 | $49k | 15,334 | May 29, 2026 |
| May 7, 2026 | EW Edwards Lifesciences Corp | AGrant or award Common Stock | +3,985 | $0.00 | $0 | 13,171 | May 8, 2026 |
| May 7, 2026 | EW Edwards Lifesciences Corp | AGrant or award Common Stock | +3,020 | $0.00 | $0 | 16,191 | May 8, 2026 |
| May 8, 2026 | EW Edwards Lifesciences Corp | FTax withholding Common Stock | -289 | $82.76 | $24k | 15,902 | May 8, 2026 |
| May 7, 2026 | EW Edwards Lifesciences Corp | AGrant or award Employee Stock Option (Right to Acquire)derivative | +6,745 | $0.00 | $0 | 6,745 | May 8, 2026 |
| Feb 22, 2026 | EW Edwards Lifesciences Corp | FTax withholding Common Stock | -176 | $79.78 | $14k | 9,089 | Feb 23, 2026 |
| Nov 13, 2025 | EW Edwards Lifesciences Corp | AGrant or award Common Stock | +1,160 | $0.00 | $0 | 9,183 | Nov 13, 2025 |
| Sep 13, 2025 | EW Edwards Lifesciences Corp | FTax withholding Common Stock | -262 | $77.57 | $20k | 7,927 | Sep 15, 2025 |
| May 8, 2025 | EW Edwards Lifesciences Corp | AGrant or award Common Stock | +3,335 | $0.00 | $0 | 8,107 | May 9, 2025 |
| May 8, 2025 | EW Edwards Lifesciences Corp | AGrant or award Employee Stock Option (Right to Acquire)derivative | +5,670 | $0.00 | $0 | 5,670 | May 9, 2025 |
| Feb 22, 2025 | EW Edwards Lifesciences Corp | FTax withholding Common Stock | -176 | $73.30 | $13k | 4,684 | Feb 24, 2025 |
Questions about Andrew M. Dahl
Answered from the filings on this page, as of the latest one.
Is Andrew M. Dahl buying or selling?
In the last 12 months Andrew M. Dahl reported 0 open-market buys worth $0 and 1 open-market sell worth $49k on SEC Form 4; the latest was sold $49k of EW on May 29, 2026. Grants, option exercises and tax withholding are not counted.
How did Andrew M. Dahl's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Andrew M. Dahl has 0.
Where does Andrew M. Dahl file Form 4?
Andrew M. Dahl has filed Form 4 at EW (Edwards Lifesciences Corp) as SVP, Corporate Controller. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.